Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 5/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6000410 | 0.89 | HTR2A (0.39) | HTR2AHTR2CHTR1ASLC6A4 | |
| Formic Acid SCHEMBL6000453 | 0.83 | HTR2A (0.37) | HTR2AHTR2CHTR1ASLC6A4NR3C1 | |
| Formic Acid SCHEMBL6000448 | 0.82 | HTR2A (0.37) | HTR2AHTR2CHTR1ASLC6A4NR3C1 | |
| SCHEMBL5999503 | 0.81 | KCNH2 (0.34) | HTR2ASLC6A4CHRM2CHRM1CHRM3 | |
| SCHEMBL6000267 | 0.81 | FFAR1 (0.38) | HTR2ASLC6A4RAB9A | |
| SCHEMBL6000432 | 0.73 | HTR2A (0.32) | HTR2ASLC6A4 | |
| Formic Acid SCHEMBL6000411 | 0.72 | PARP1 (0.38) | HTR2AHTR2CHTR1ASLC6A4 | |
| Formic Acid SCHEMBL6000403 | 0.71 | SLC6A4 (0.47) | HTR2AHTR2CHTR1ASLC6A4 | |
| SCHEMBL5999794 | 0.69 | HTR2A (0.33) | HTR2ASLC6A4 | |
| SCHEMBL6000417 | 0.65 | HTR2A (0.37) | HTR2AHTR2CHTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | PFIZER INC | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058361-A1 | Therapeutic diphenyl ether ligands | HTR2B, HTR2C, HTR3B | HTR2A 7/4885HTR2C 2/4885HTR1A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.